---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-001826"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:53:35.136531+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BiomX reports FY2024 results, $12M financing, Phase 2 DFO readout imminent

## Summary
- Phase 2 topline results for BX211 in diabetic foot osteomyelitis expected by end of March 2025.
- February 2025 financing raised ~$12M gross proceeds to support BX004 Phase 2b readout in Q1 2026.
- Cash and restricted cash $18.0M at Dec 31, 2024; plus $12M raised in Feb 2025; runway into Q1 2026.
- FY2024 net loss $17.7M (vs $26.2M); R&D expenses $24.7M; impairments on goodwill, IPR&D, and assets.
- Non-dilutive funding from DHA for BX211 totaled $36.8M to date; manufacturing delays for BX004 resolved.

## SEC filing metadata
- accession: 0001013762-25-001826
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000101376225001826/0001013762-25-001826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000101376225001826/ea0235496-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-001826
- JSON: https://secwatch.observer/filing/0001013762-25-001826.json
- Plain text: https://secwatch.observer/filing/0001013762-25-001826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.